References
- Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-64. 10.1038/nrc3239
- Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373: 123-35. 10.1056/NEJMoa1504627
- Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015; 373: 1627-39. 10.1056/NEJMoa1507643
- Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015; 372: 2018-28. 10.1056/NEJMoa1501824
- Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016; 375: 1823-33. 10.1056/NEJMoa1606774
- Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbé C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15: 7412-20. 10.1158/1078-0432.CCR-09-1624.
- Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 2017; 18: e143-52. 10.1016/S14702045(17)30074-8
- Hodi FS, Hwu WJ, Kefford R. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol 2016; 34: 1510-7. 10.1200/JCO.2015.64.0391
- Kurra V, Sullivan RJ, Gainor JF, Hodi FS, Gandhi L, Sadow CA, et al. Pseudoprogression in cancer immunotherapy: rates, time course and patient outcomes. [abstract]. J Clin Oncol 2016; 34(15 Suppl): No. 6580. 10.1200/JCO.2016.34.15_suppl.6580
- Hammer M, Bagley S, Aggarwal C, Bauml J, Nachiappan AC, Simone CB 2nd, et al. Thoracic imaging of non-small cell lung cancer treated with antiprogrammed death receptor-1 therapy. Curr Prob Diagn Radiol 2018 [Epub ahead of print]. 10.1067/j.cpradiol.2018.01.005
- Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015; 373: 1627-39. 10.1056/NEJMoa1507643
- Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2015; 33: 2004-12. 10.1200/JCO.2014.58.3708
- Chiou VL, Burotto M. Pseudoprogression and immune-related response in solid tumors. J Clin Oncol 2015; 33: 3541-3. 10.1200/JCO.2015.61.6870
- Nishino M, Ramaiya NH, Chambers ES, Adeni AE, Hatabu H, Jänne PA, et al. Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients. J Immunother Cancer 2016; 4: 84. 10.1186/s40425-016-0193-2
- Kim HK, Heo MH, Lee HS, Sun JM, Lee SH, Ahn JS, et al. Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors. Cancer Chemother Pharmacol 2017; 80: 591-8. 10.1007/s00280-017-3396-4
- Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47. 10.1016/j.ejca.2008.10.026
- Sarfaty M, Moore A, Dudnik E, Peled N. Not only for melanoma. Subcutaneous pseudoprogression in lung squamous-cell carcinoma treated with nivolumab: a case report. Medicine (Baltimore) 2017; 96: e5951. 10.1097/MD.0000000000005951
- Kolla BC, Patel MR. Recurrent pleural effusions and cardiac tamponade as possible manifestations of pseudoprogression associated with nivolumab therapy - a report of two cases. J Immunother Cancer 2016 4: 80. 10.1186/s40425-016-0185-2
- Izumida T, Kawagishi Y, Tsuji H. Pseudoprogression in lung adenocarcinoma during treatment with nivolumab. BMJ Case Reports 2017; doi:10.1136/ bcr-2017-219919. [cited 2018 Feb 2]. Available at http://casereports.bmj.com/content/2017/bcr-2017-219919.full
- Kumagai T, Kimura M, Inoue T, Tamiya M, Nishino K, Imamura F. Delayed pseudoprogression of lung adenocarcinoma accompanied with interstitial lung disease during chemotherapy after nivolumab treatment. Thorac Cancer 2017; 8: 275-7. 10.1111/1759-7714.12431
- Hochmair MJ, Schwab S, Burghuber OC, Krenbek D, Prosch H. Symptomatic pseudo-progression followed by significant treatment response in two lung cancer patients treated with immunotherapy. Lung Cancer 2017; 113: 4-6. 10.1016/j.lungcan.2017.08.020
- Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 2011; 331: 1565-70. 10.1126/science.1203486
- Garon EB, Naiyer AR, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015; 372: 2018-28. 10.1056/NEJMoa1501824
- Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WEE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373: 123-35. 10.1056/NEJMoa1504627
- Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016; 375: 1823-33. 10.1056/NEJMoa1606774
- Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 2017; 389: 255-65. 10.1016/S01406736(16)32517-X
- Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, openlabel, phase 2 randomised controlled trial. Lancet 2016; 387: 1837-46. 10.1016/S0140-6736(16)00587-0
- Peters S, Gettinger S, Johnson ML, Jänne PA, Garassino MC, Christoph D, et al. Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1-selected advanced non-smallcell lung cancer (BIRCH). J Clin Oncol 2017; 35: 2781-9. 10.1200/ JCO.2016.71.9476
- Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74. 10.1016/j.cell.2011.02.013
- Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Re Oncol Hematol 2013; 88: 218-30. 10.1016/j.critrevonc.2013.03.010
- Kang MH, Go SI, Song HN, Lee A, Kim SH, Kang JH, et al. The prognostic impact of the neutrophil-to-lymphocyte ratio in patients with small-cell lung cancer. Br J Cancer 2014; 111: 452-60. 10.1038/bjc.2014.317
- Templeton AJ, McNamara MG, Šeruga B, Vera-Badillo FE, Aneja P, Ocaña A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 2014; 106: dju124. 10.1093/jnci/dju124
- Bagley SJ, Kothari S, Aggarwal C, Bauml JM, Alley EW, Evans TL, et al. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. Lung Cancer 2017; 106: 1-7. 10.1016/j.lungcan.2017.01.013
- Ferrucci PF, Gandini S, Battaglia A, Alfieri S, Di Giacomo AM, Giannarelli D, et al. Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients. Br J Cancer 2015; 112: 1904-10. 10.1038/bjc.2015.180
- Vrankar M, Zwitter M, Kern I, Stanic K. PD-L1 expression can be regarded as prognostic factor for survival of non-small cell lung cancer patients aſter chemoradiotherapy. Neoplasma 2018; 59: 101-6. 10.4149/ neo_2018_170206N77
- Wang A, Wang HY, Liu Y, Zhao MC, Zhang HJ, Lu ZY, et al. The prognostic value of PD-L1 expression for non-small cell lung cancer patients: a metaanalysis. Eur J Surg Oncol 2015; 41: 450-6. doi:10.1016/j.ejso.2015.01.020
- Zhou Z, Zhan P, Song Y. PD-L1 over-expression and survival in patients with non-small cell lung cancer : a meta-analysis. Transl Lung Cancer Res 2015; 4: 203-8. 10.3978/j.issn.2218-6751.2015.03.02
- Saba L, Poreu M, Schmid B, Flohr T. Dual energy CT: basic principles. In: Cecco CN, Laghi A, Schoepf UJ, Meinel FG, editors. Dual energy CT in oncology Cham, Germany: Springer. p. 1-20.
- Bensch F, Veen E, Jorritsma A. First-in-human PET imaging with the PD-L1 antibody 89Zr-atezolizumab. Paper presented at: AACR Annual Meeting, Washington Convention Center, April 2, 2017. CT017.